Brian Nowosielski

Leading health care economist and public policy expert John C. Goodman, PhD, breaks down what various supply chain entities can expect with TrumpRx.

Researchers want to bolster evidence regarding the known link between maternal mental health and childhood nutritional status.

Episode 5 explores insulin management as well as the insulin products, doses, and administration tools all pharmacists should be familiar with for their patients with diabetes.

President Trump signed into law HR 2483, also known as the SUPPORT for Patients and Communities Reauthorization Act of 2025.

In part 3 of our interview with John C. Goodman, PhD, he discusses how TrumpRx could impact the drug supply chain—specifically PBMs.

Researchers explore community-acquired pneumococcal-related hospital admissions among adults from 2000 to 2019 and assess pneumococcal immunization’s impact after the year 2015.

In an exploration of the National Retail Data Monitor, researchers determine how OTC sales contributed to disease surveillance.

John C. Goodman, PhD, discusses TrumpRx’s impact on patients and pharmacies, comparing this administration’s approach with the previous Biden Administration.

John C. Goodman, PhD, senior fellow at the Independent Institute, discusses TrumpRx and its goals for patients’ OOP drug costs.

The agency’s findings spur promises of significant change to the development and recommendations surrounding various immunizations.

Researchers investigate serotype distribution and antimicrobial resistance among children in Mexico with pneumococcal meningitis.

Jeffrey Bratberg, PharmD, BCPS, and Michelle Caetano, PharmD, BCACP, CVDOE, CDOE, BCPT, discuss the Pharmacy Bridge resource and pharmacists’ role in OUD management.

Patient safety organizations began in the early 21st century to improve health care safety measures amongst various providers’ practices.

Researchers conduct a cost-effectiveness analysis to uncover the public health and economic impacts of PCV20 among Australian children.

In this episode, host Taylor Watterson, PharmD, PhD, welcomes Wesley Sparkmon, PhD, MPH, assistant professor of pharmacy sciences at Creighton University.

Novo Nordisk announced results of the evoke and evoke+ phase 3 trials on semaglutide’s use in treating Alzheimer disease progression.

Catie Stimmel, PharmD, discusses the pharmacist’s role in ensuring PSOs operate at their intended capabilities.

Catie Stimmel, PharmD, explores the confidentiality and non-punitive processes that are crucial in driving value toward patient safety organizations.

Catie Stimmel, PharmD, discusses what PSOs are and how they are protecting patients all across the US health care system.

Experts at the Milken Institute address better ways of adopting pharmacy services within the greater health care ecosystem.

After nearly 20 years of pneumococcal conjugate vaccine use in the Portuguese vaccine schedule, researchers explore serotype distribution in bacteria causing adult invasive pneumococcal disease (IPD).

A conversation with NCPDP’s Rick Sage explored the lasting effects on pharmacy stemming from the record-breaking government shutdown.

Regeneron Pharmaceuticals’ newest drug will be the first and only approved flexible treatment option for retinal vein occlusion.

In this episode, Natalie DiPietro Mager, PharmD, PhD, MPH, meets with pharmacists from Ohio State University to discuss smoking trends among women.

Rick Sage, executive vice president of innovation and standards with the NCPDP, discusses the nuances of billing under either Medicare Part B or D.

Researchers explore the no-cost uptake of 2 separate emergency contraception methods.

Study authors explore online purchasing habits for prescription-only and OTC medications.

Researchers explore OTC medication misuse among adults over 65 in Saudi Arabia.

Researchers address the potential association of access to maternal care with the increased risk of infant mortality.

With disease cases increasing substantially between 2012 and 2024, higher-valent vaccines are necessary to protect against nonvaccine serotypes and invasive pneumococcal disease.